# To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)

> **NCT01406002** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 26 (actual)

## Conditions studied

- Pharmacokinetics of Darexaban and Metabolites
- Healthy Subjects

## Interventions

- **DRUG:** darexaban
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01406002
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2013-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406002, "To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01406002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*